Cascadian Therapeutics
Oncothyreon Inc. (Form: 8-K, Received: 09/08/2011 06:24:09)





Washington, DC 20549







Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 7, 2011




(Exact name of registrant as specified in its charter)




Delaware   001-33882   26-0868560

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification No.)

2601 Fourth Avenue, Suite 500

Seattle, Washington 98121

(Address of principal executive offices, including zip code)

(206) 801-2100

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 8, 2011, Oncothyreon Inc. (the “Company”) announced that Dr. Robert Kirkman, President and Chief Executive Officer of the Company, has taken a temporary medical leave of absence, effective September 12, 2011. During Dr. Kirkman’s absence, Dr. Christopher Henney, who has served as the Chairman of the Company’s board of directors since 2006, will assume Dr. Kirkman’s duties and responsibilities.

In satisfaction of the disclosure required pursuant to Sections 401(b) and 401(e) of Regulation S-K, Part III, Item 10 of Company’s 2011 Annual Report on Form 10-K, filed with the SEC on March 14, 2011, is incorporated by reference herein.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.





/s/ Robert L. Kirkman, M.D.

  Robert L. Kirkman, M.D.
  President and Chief Executive Officer

Date: September 7, 2011